The Study
Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease
This study watched what happened when doctors gave one medicine (febuxostat) or another (allopurinol) to people with kidney problems. It found that febuxostat lowered uric acid more, but both medicines did about the same for kidney health. But since doctors chose which medicine to give, we can't say one caused the difference—it might just be that sicker people got one medicine and healthier people got the other.
Analysis score
Maximum 72 for a cohort study.
Where the score came from
Two pills, febuxostat and allopurinol, lower uric acid in people with kidney disease. This study checked which one works better over 2.5 years.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 567 / 100
Quality score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Even though febuxostat lowers uric acid better, that didn’t mean kidneys got better or worse — so lowering uric acid alone didn’t protect kidneys in this group.
- 2Febuxostat lowered uric acid more (by 0.92 mg/dL every 3 months) and kept it under 6 mg/dL more often.
- 3But both pills did the same to kidney function — neither slowed decline.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Scientific Reports
Year
2020
Authors
Yueh-Lung Peng, Y. Tain, Chien-Te Lee, Yi-Hsn Yang, Yaw-Bin Huang, Y. Wen, Chien-Ning Hsu
Related Content
Claims (4)
In adults with chronic kidney disease, febuxostat lowers uric acid levels more than allopurinol over 3 months and keeps more patients below a target uric acid level for most of the time, but neither drug slows the decline in kidney function over 2.5 years.
In people with chronic kidney disease, keeping blood uric acid levels below 6 mg/dL for most of the time reduces uric acid levels, but it does not change how quickly kidney function declines over 2.5 years when comparing two common medications, febuxostat and allopurinol.
In people with chronic kidney disease, taking more urate-lowering medication per day leads to lower blood uric acid levels, but taking the medication consistently on 80% or more of days does not lead to better kidney function than taking it at standard levels.
Among patients with chronic kidney disease, taking febuxostat or allopurinol leads to the same rate of decline in kidney function over 2.5 years when accounting for initial kidney health, other medical conditions, and adherence to medication.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.